Roger Howe, PhD, Executive Chairman of Stemedica Cell Technologies, Inc.” and “Ike W. Lee, Ph.D., President and Chief Technology Officer of the ANC Bio Group Sign Joint Venture Agreement.

San Diego, CA (openPR) 5 October 2010

Stemedica International, SA (â? Stemedicaâ ????), a wholly owned subsidiary of Stemedica Cell Technologies, Inc. announced the signing of an agreement for a joint venture with the ANC Bio, a global manufacturer of products to form on stem cells. The new company, to develop StemedicaAnC Stemedica produce stem cells for the treatment of ischemic stroke and other degenerative diseases. The initial production capacity of this alliance will be sufficient to meet product the league? S projections of revenues over five years with extension options for the production of stem cells more products to the growth in long-term global market expected to meet stem cells.

ANCA? s biomanufacturing facility was built at an estimated cost of $ 120,000,000 over five years. â? The synergy between Stemedicaâ? s technology, and Anca? s technologically advanced production facility StemedicaAnC position as the world leader in stem cell production, â? Said Nicolas Tankovich, MD, PhD, Stemedicaâ? s Chairman and Chief Medical Officer. â? The facility will offer StemedicaAnC the opportunity to meet their various allogeneic stem cell products manufactured to international safety and quality standards by the U.S. FDA, Swiss Medic, the European regulatory agency and Korea established? ? the FDA. > Â ????

â? We are pleased with Stemedica accelerate work to the development of stem cell therapy, â? Said Alex Choi, President and CEO of CNA Group trillion â? This joint venture will stem cell products institutions around the world who are conducting clinical trials and stem cell research.â ????

“We have a lot of time and effort in looking for a manufacturing cell strains of best-in class to invest our technology, a place?” said Roger J. Howe, PhD, Executive Chairman of Stemedica. â? Bio ANC offers an excellent choice for our international business development> strategy.â ????

â? It is an exciting time for both companies, â? Ike said W. Lee, Ph.D., President and Chief Technology Officer of the ANC trillion â? Stemedicaâ? s advanced technologies and operating systems is an important addition to the ANC are bioA? s manufacturing facilities. I look forward to working with her team of scientists and engineers. Â p> ???? The joint venture will represent both the ANC and Bio Stemedica be supervised by a board. The planning of the operations is expected to begin later this year.


About

Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies, Inc. (www.stemedica.com) is a specialty biopharmaceutical company, develops and manufactures adult best-in-class stem cell factor and stem cell lines for use by research institutions and hospitals for pre-approved and clinical trials on humans. The company is currently developing regulatory pathways in neurology, cardiology, ophthalmology, wound care and dermatology.Stemedica in San Diego, California. For more information about Stemedica Cell Technologies, Inc. to Dave McGuigan dmcguigan (at) stemedica.com

About CNA Group Bio

ANC Bio Group, a Korean company of three business units: the Department of Cellular Therapy, which includes a cell culture in the state of the art cGMP facility, which manufactures artificial organs division designs, markets and human artificial organs such as kidney dialysis and artificial heart combined and developed lung machines, and the vaccine division manufactures and sells various types of cell culture vaccines, including influenza, influenza, anthrax and Alzheimer ????. For more information on the ANC-Bio, visit www.ancbio.com.


>

clear = “all”
Residential treatment centers for eating disorders